Corbus Pharmaceuticals (CRBP) Earning Somewhat Favorable Press Coverage, Analysis Finds
News coverage about Corbus Pharmaceuticals (NASDAQ:CRBP) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Corbus Pharmaceuticals earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.5792938263575 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) opened at $7.20 on Thursday. Corbus Pharmaceuticals has a twelve month low of $5.30 and a twelve month high of $10.50.
Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.02. The firm had revenue of $0.80 million for the quarter. Corbus Pharmaceuticals had a negative net margin of 1,040.41% and a negative return on equity of 96.02%. analysts anticipate that Corbus Pharmaceuticals will post -0.61 earnings per share for the current year.
A number of analysts recently issued reports on CRBP shares. ValuEngine downgraded shares of Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, September 13th. Noble Financial increased their price target on shares of Corbus Pharmaceuticals from $16.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th. Cantor Fitzgerald reissued a “buy” rating and set a $24.00 price target on shares of Corbus Pharmaceuticals in a report on Wednesday, September 20th. Finally, BidaskClub raised shares of Corbus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Two equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. Corbus Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $23.67.
In related news, Director David P. Hochman acquired 5,000 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were acquired at an average cost of $6.90 per share, with a total value of $34,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David P. Hochman acquired 10,000 shares of the firm’s stock in a transaction on Friday, November 10th. The shares were bought at an average cost of $7.08 per share, for a total transaction of $70,800.00. Following the completion of the acquisition, the director now owns 459,500 shares of the company’s stock, valued at $3,253,260. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 25,336 shares of company stock worth $175,632. Insiders own 11.90% of the company’s stock.
WARNING: This story was published by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/12/14/corbus-pharmaceuticals-crbp-earning-somewhat-favorable-press-coverage-analysis-finds.html.
About Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.